2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-18002
    Oleanolic acid derivative 1 1724-18-1 98%
    Oleanolic acid derivative 1 is an oleanolic acid derivative, which is a novel triterpenoid-steroid hybrid molecule.
    Oleanolic acid derivative 1
  • HY-18003
    Oleanolic acid derivative 2 211516-63-1 98%
    Oleanolic acid derivative 2 is an oleanolic acid derivative, which is a novel triterpenoid-steroid hybrid molecule.
    Oleanolic acid derivative 2
  • HY-18228
    CP-352664 1097883-05-0 98%
    CP-352664 is a JAK inhibitor. CP-352664 has a inhibitoinhibits JAK3 with an EC50 value of 210 nM. CP-352664 is promising for research of organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.
    CP-352664
  • HY-18263
    Elubrixin hydrochloride 688763-65-7 98%
    Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin hydrochloride inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin hydrochloride has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.
    Elubrixin hydrochloride
  • HY-18617
    rel-SB-612111 hydrochloride 371980-94-8 98%
    rel-SB-612111 hydrochloride is a novel and potent human opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki=0.33 nM). rel-SB-612111 hydrochloride exhibits selectivity for μ-, κ- and δ-receptors with Ki values of 57.6 nM, 160.5 nM and 2109 nM, respecticely. rel-SB-612111 hydrochloride effectively antagonizes the pronociceptive action of Nociceptin (HY-P0183) in an acute pain model.
    rel-SB-612111 hydrochloride
  • HY-18618
    SB-612111 371980-98-2 98%
    SB-612111 is a novel and potent opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki=0.33 nM). SB-612111 exhibits selectivity for μ-, κ- and δ-receptors with Ki values of 57.6 nM, 160.5 nM and 2109 nM, respecticely. SB-612111 effectively antagonizes the pronociceptive action of Nociceptin (HY-P0183) in an acute pain model.
    SB-612111
  • HY-18709
    Tyk2-IN-3 1779493-12-7 98%
    Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC50 of 485 nM.
    Tyk2-IN-3
  • HY-18759
    BMS-751324 948842-66-8 98%
    BMS-751324 is a p38α MAPK inhibitor. BMS-751324 equips a precursor of carbamyl-methyl linkage, containing esters and phosphate functional groups derived from hydroxyphenylacetic acid (HPA). BMS-751324 effectively inhibits foot swelling and LPS-induced TNFα production in an arthritic rat model.
    BMS-751324
  • HY-18900
    Nec-4 1041644-43-2 98%
    Nec-4, a tricyclic derivative, is a potent receptor interacting protein 1 (RIP1) inhibitor, with an IC50 of 2.6 μM, Ki of 0.46 μM.
    Nec-4
  • HY-18970
    TG6-129 1164464-14-5 98%
    TG6-129 is a selective antagonist of the EP2 receptor. TG6-129 reduces the expression of inflammatory factors induced by butaprost in P388D1 macrophages.
    TG6-129
  • HY-19017
    Fenclozine 75626-98-1 98%
    Fenclozine is a non-steroidal antiinflammatory agent.
    Fenclozine
  • HY-19025
    CV-159 86384-98-7 98%
    CV-159 is a unique dihydropyridine Ca2+ antagonist with an anti-calmodulin (CaM) action, and has antiinflammatory activities.
    CV-159
  • HY-19042
    YM-16638 104073-72-5 98%
    YM-16638 is an orally active leukotriene (LT) antagonist. YM-16638 can inhibit the production of LTC4, LTD4, and LTE4 in guinea pig trachea, with IC50 values of 0.05 μM, 0.16 μM, and 0.096 μM, respectively. YM-16638 has a dose-dependent inhibitory effect on antigen-induced early and late respiratory responses in allergic sheep.
    YM-16638
  • HY-19114
    WY-50295 123016-21-7 98%
    WY-50295 is an orally active and selective 5-lipoxygenase inhibitor. WY-5029 inhibits LTB4 formation in rat whole blood leukocytes (IC50: 40 μM and oral ED50: 18 mg/kg). WY-50295 can be used in the study of asthma and other leukotriene-dependent diseases.
    WY-50295
  • HY-19213
    L-693612 138301-71-0 98%
    L-693612 (Compd 1) is an orally active and topical carbonic anhydrase inhibitor.
    L-693612
  • HY-19232
    R-87366 144779-91-9 98%
    R-87366 is a water-soluble human immunodeficiency virus (HIV) protease inhibitor. R-87366 has potent inhibitory for HIV protease with a Ki value of 11 nM. R-87366 can be used for the research of anti-human immunodeficiency virus (HIV).
    R-87366
  • HY-19249
    Z-335 sodium 146731-14-8 98%
    Z-335 sodium is an orally active thromboxane a2 (TXA2) receptor antagonist, with IC50 values of 29.9 nM and 32.5 nM for human and Guinea pig platelets, respectively.
    Z-335 sodium
  • HY-19262
    TAK-218 156756-10-4 98%
    TAK-218 is a promising candidate as an agent tor central nervous system trauma and ischemia. TAK-218 exhibits potent scavenging activity and antioxidative activity. TAK-218 also inhibits dopamine release.
    TAK-218
  • HY-19421
    Orazamide 2574-78-9 98%
    Orazamide is an AICA orotate. Orazamide can prevent anti-TB drug-induced liver damage by downregulating the protein expression of HMGB 1 and RAGE in liver tissue and inhibiting the secretion of inflammatory factors. Orazamide can be used in research on hepatitis and liver cirrhosis.
    Orazamide
  • HY-19472
    RWJ-58643 287183-00-0 98%
    RWJ-58643 is a β-trypsin inhibitor that suppresses allergic inflammation. RWJ-58643 (100 mg) significantly reduced nasal allergy symptoms, eosinophil infiltration, and IL-5 levels at low doses. RWJ-58643 resulted in late eosinophilia and elevated IL-5 levels at high doses (300 mg and 600 mg). RWJ-58643 modulates allergic responses by inhibiting the release of β-trypsin from mast cells.
    RWJ-58643
Cat. No. Product Name / Synonyms Application Reactivity